Areteia Therapeutics

Asthma is a growing population health problem globally which carries enormous disease burden and economic consequences. There has been no new oral therapy in asthma since the 1990s, and no major oral breakthrough since the 1970s. Health systems are looking for new cost effective, safe, and convenient oral treatments to help millions of patients. We formed Areteia Therapeutics to undertake late-stage clinical trials demonstrating the clinical performance, value, and utility of a new tablet which has the potential to improve the health of patients with eosinophilic asthma worldwide.